Featured
Intra-Cellular Therapies (ITCI) Announces $350M Public Offering of Common Stock
Intra-Cellular proposes $350 million underwritten public offering. In addition, with the update of positive final-phase test results for a treatment
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.